文献速递肾癌与肾肿瘤

微血管与淋巴血管肿瘤侵犯与肾细胞癌不良预后及转移相关:临床实践验证研究

Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
PubMed 文献 · BJU Int · 2017-09-10

本研究在三个学术中心前瞻性收集行根治性或保留肾单位手术的肾细胞癌患者数据,验证微血管侵犯(MVI)和淋巴血管侵犯(LVI)的预后价值。MVI见于201/747例(26.9%),LVI见于32/573例(5.5%),二者均与晚期TNM分期、高Fuhrman分级及肉瘤样特征相关(均P<0.001)。多变量分析中MVI为独立预后因素(HR 2.09;P=0.001),LVI为同步转移最强的相关因素(OR 4.73,95%CI 1.84-12.14;P=0.001)。

要点

  • MVI见于26.9%患者,与晚期TNM分期、高Fuhrman分级及肉瘤样特征相关(均P<0.001)。
  • 多变量分析中MVI为独立预后因素(HR 2.09;P=0.001),并独立预测同步转移(OR 2.7;P=0.001)。
  • LVI见于5.5%患者,为同步转移最强相关因素(OR 4.73,95%CI 1.84-12.14;P=0.001)。

核心结论

  • 本研究验证LVI和MVI为肾细胞癌不良预后的预后因素。
  • 作者认为这些发现支持在临床常规中评估这两项变量,以促进随访方案中的生存预后判断及辅助治疗试验的分组。

研究设计与样本

  • 前瞻性收集来自三个学术中心的行根治性或保留肾单位手术的肾细胞癌患者数据。
  • MVI和LVI由经验丰富的病理学家在诊断时采用标准染色方案判定。
  • 采用Fisher精确检验、二元logistic回归分析及单变量和多变量Cox比例风险回归模型评估MVI和LVI与临床病理数据、转移扩散及癌症特异性生存(CSS)的关联。

主要发现

  • MVI见于201/747例(26.9%),与晚期TNM分期、高Fuhrman分级及肉瘤样特征相关(均P<0.001),并与更高的转移扩散率相关。
  • LVI见于32/573例(5.5%),与晚期TNM分期、高Fuhrman分级及肉瘤样特征相关(均P<0.001);LVI阳性患者中三分之二死亡(P<0.001)。
  • 单变量分析中,LVI和MVI均与全部患者、透明细胞肾细胞癌(ccRCC)及局限性肾细胞癌的CSS显著相关(均P<0.001)。
  • 多变量分析中,MVI为独立预后因素(HR 2.09;P=0.001);MVI为同步转移的独立预测因素(OR 2.7;P=0.001),而大血管侵犯不是(P=0.895)。
  • LVI为全部患者及ccRCC亚组中与同步转移最强的相关因素(OR 4.73,95%CI 1.84-12.14;P=0.001)。

临床怎么用

  • 作者认为这些发现支持在临床常规中评估MVI和LVI,以促进随访方案中的生存预后判断及辅助治疗试验的分组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To validate microvascular (MVI) and lymphovascular (LVI) invasion as prognostic factors in patients with renal cell carcinoma (RCC). PATIENTS AND METHODS: Data of patients with RCC who underwent radical or nephron-sparing surgery were prospectively collected from three academic centres. The occurrence of MVI and LVI was determined with standard staining protocols by experienced pathologists at the time of diagnosis. The association of MVI and LVI with clinicopathological data, metastatic spread, and cancer-specific survival (CSS) were evaluated with Fisher's exact tests, binary logistic regression analyses, and univariable and multivariable Cox proportional hazard regression models. RESULTS: MVI was present in 201 of 747 patients (26.9%) and was associated with advanced Tumour-Node-Metastasis (TNM) stages, high Fuhrman grades, and sarcomatoid features (all P < 0.001). MVI was associated with a higher rate of metastatic spread. LVI was present in 32 of 573 patients (5.5%) and was associated with advanced TNM stages, high Fuhrman grade, and sarcomatoid features (all P < 0.001). Two-thirds of LVI-positive patients died (P < 0.001). Both LVI and MVI were significantly associated with CSS in all patients, clear cell RCC (ccRCC), and localised RCC in univariable analysis (all P < 0.001). On multivariable analysis, presence of MVI was identified as an independent prognostic factor (hazard ratio 2.09; P = 0.001). Moreover, MVI [odds ratio (OR) 2.7; P = 0.001] and not macrovascular invasion (P = 0.895) was an independent predictor of sychronuous metastatic spread. LVI was the strongest factor associated with sychronous metastatic spread (OR 4.73, 95% confidence interval 1.84-12.14; P = 0.001) in all patients and in the subgroup of patients with ccRCC (P = 0.001). CONCLUSIONS: The present study validated LVI and MVI as prognostic factors for poor outcome in RCC. These findings endorse an evaluation of both variables in the clinical routine setting to facilitate survival prognostication in follow-up protocols and for assignment to adjuvant treatment trials.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Bedke J, Heide J, Ribback S, et al. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. BJU Int. 2017. PMID: 28803448. doi:10.1111/bju.13984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。